In AD and normal controls (NCs), links between brain atrophy and CSF biomarkers have been reported, supporting the hypothesis that the biomarkers reflect regional or global neurotoxicity related to protein dysmetabolism.8 Studies in AD have found associations between lower CSF Aβ42 and CA1 deformation, and hippocampal atrophy and higher T- and phosphorylated tau, and hippocampal, parahippocampal, and ERC atrophy.8,32 However, very few studies have assessed the relationship between CSF biomarkers and atrophy in PD. This evidence concerns the gene MAPT and Parkinson disease.